| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
It was revealed that canine hemangiosarcoma cells, mammary tumor cells, and malignant melanoma cells released microparticles and exhibited tissue factor-dependent procoagulant activity. Tissue factor-dependent procoagulant activity in plasma was not increased in dogs with disseminated intravascular coagulation (DIC) caused by a malignant tumor. Further study is needed to elucidate the significance of tissue factor-dependent procoagulant activity for diagnosis and prognosis of DIC in dogs. Simvastatin significantly inhibited the cell proliferation of several types of canine tumor cells, although it could not inhibit the pro-coagulant activity in these cells.
|
